Long Covid (LC)-REVITALIZE - A Long Covid Repurposed Drug Study (NCT06928272)
LC-REVITALIZE - A Long Covid Repurposed Drug Study
🩺 Plain-English Summary (8th-Grade Level)
The Long-Covid (LC)-Revitalize clinical study is testing repurposed drug treatments for Long Covid, involving adult participants from Brazil, Canada, Italy, Uganda, the United States, and Zambia. To qualify, participants must have had Covid-19 and experienced Long Covid symptoms for at least three months. The main goal of the study is to determine whether the drug treatments can improve symptoms in five key areas: 1) fatigue, 2) breathing, 3) memory, thinking, and communication, 4) muscle and joint pain, and 5) circulation. A secondary goal is to assess changes in the body, such as reducing inflammation, as well as to confirm the safety and tolerability of the treatments. In the first phase, 348 participants will take either one of two existing medications (upadacitinib or pirfenidone) or a placebo (a pill with no active ingredient) for three months. Although these medications are not yet approved for Long Covid, they are authorized for use in treating other health conditions. This study is adaptive, meaning it may adjust based on early results. In the second phase, the study could continue testing the most effective drug(s) against a placebo with new participants, explore combinations of drugs to see if they improve results, or discontinue the drugs if they prove ineffective or unsafe and test alternative treatments.
Who can join: Review the eligibility criteria below.
Location: Laura Rodriguez Research Institute — San Diego, California
Age range: 18 Years to 65 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (9 Sites)
- Laura Rodriguez Research Institute — San Diego, California
- Ini-Fiocruz — Rio de Janeiro, Rio de Janerio
- Institut de Recherches Cliniques de Montréal (IRCM) — Montreal, Quebec
- Centre de Recherche du CHUS (CRCHUS) — Sherbrooke, Quebec
- INMI Lazzaro Spallanzani IRCCS — Roma, Roma
- Sapienza Università di Roma — Roma, Roma
- Università degli Studi di Modena e Reggio Emilia — Modena,
- Joint Clinical Research Centre (JCRC) — Kampala, Kampala
- University Teaching Hospital — Lusaka, Lusaka Province
📞 Contact the Study Coordinator
Phone: (519) 685-8500
Email: stephanie.perkin@lhsc.on.ca
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Long COVID
- Ensitrelvir for Viral Persistence and Inflammation in People Experiencing Long COVID — San Francisco, California
- The Long COVID Treatment Trial — La Jolla, California
- tVNS in Long COVID-19 — New York, New York
- Nutritional Management of Post COVID-19 Cognitive Symptoms — Edmonton, Alberta
- Pain in Long COVID-19: the Role of Sleep — Boston, Massachusetts
- Long COVID Immune Profiling — Nashville, Tennessee
Explore by condition: All Long COVID clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.